RenovoRx Posts 136% Revenue Surge to $563K and Raises $10M
RenovoRx reported a record $563,000 in Q1 revenue, up 136% from Q4 2025, while expanding its commercial cancer centers from 8 to 16 and adding 32 new centers in its pipeline. The company also closed an oversubscribed private placement raising $10 million to fund operations through its Phase III trial.
1. Record Q1 Revenue Growth
RenovoRx delivered $563,000 in Q1 2026 revenue, representing a 136% increase over Q4 2025 and marking its highest quarterly sales to date.
2. Commercial Expansion Plans
The company doubled its active commercial cancer centers from 8 at the end of 2025 to 16 as of May 2026, while maintaining a pipeline of 32 additional centers in various stages of evaluation.
3. Funding via Private Placement
RenovoRx closed an oversubscribed private placement that generated approximately $10 million in gross proceeds, bolstering its cash reserves for ongoing commercial expansion and clinical development.
4. Investment Costs and Trial Timeline
R&D expenses reached $1.2 million and SG&A costs were $2.7 million in Q1, with the company projecting reduced cash burn later this year and expecting Phase III TIGER-PACT trial data by mid to late 2027.